Analytical Evidence Report

HPLC-UV results for the submitted Cagrilintide sample

REPORT NUMBER
DAYL-CAGR-10-102626

GENERATED
November 04, 2026

Cagrilintide

Sample vial 3, injection 1 | Client report DAYL-CAGR-10-102626

Results and chromatograms

Lot # TNPS-CAG10-001 | Client: TrueNorth Peptide Supply

Laboratory Analysis: Testides analytical laboratory

Laboratory identity and applicable credentials are maintained by Testides and are available to regulatory authorities where required by law.

VIAL PHOTOGRAPH


SAMPLE INFORMATION	
Peptide:	**Cagrilintide**
Client ID:	**DAYL-CAGR-10-102626**
Label claim:	**10 mg**
Injection:	**10 uL, 214 nm**

ANALYSIS	
Method:	**HPLC-UV**
Channel:	**214 nm**
Integration:	**Laboratory**
Identity:	**Conforms**

RUN DETAILS	
Run date:	**Nov 03, 2026**
Acquired:	**21:12:51 UTC**
Run time:	**35 min**
Laboratory:	**Testides analytical laboratory**

RESULTS AT A GLANCE

PROJECTED AMOUNT	HPLC PURITY	CONTENT VS. LABEL	IDENTITY
13.11 mg*	**99.86%**	**131.1%**	**Conforms**
EXTRAPOLATED; OUTSIDE CURVE	214 NM AREA PERCENT*	13.11 MG OF 10 MG CLAIMED	RETENTION MATCHES REFERENCE**

CHROMATOGRAM

As integrated by the laboratory - every plotted reading, with its baselines and peak marks



HPLC PURITY (214 NM)

Main peak area %	Integrated peaks	Smallest peak integrated	Recovered chromatogram
99.86%	**2**	**0.14%**	**±0.25%**
Laboratory integration	Counted in the total	Of total area	Area vs. laboratory table

Purity is the main peak's share of the total peak area the laboratory integrated at 214 nm. The smallest peak it integrated was 0.14% of the total; the laboratory does not state a reporting threshold, so peaks below the ones it integrated are not counted. Integrating the recovered chromatogram reproduces its main-peak area to within 0.25%. This result rests on a single injection.

The chromatogram is recovered point for point from the laboratory's report: 301 plotted readings from 20.00 to 25.00 min, joined as drawn; nothing is smoothed or resampled.

* HPLC purity is the main peak's share of all peak area the laboratory integrated; every peak is itemised on page 3.

** Identity conforms: the retention time is within ±8% of the reference standard on the same method (-2.04%).

Cagrilintide

Sample vial 3, injection 1 | Client report DAYL-CAGR-10-102626

Reference comparison and calculation

Lot # TNPS-CAG10-001 | Client: TrueNorth Peptide Supply

CONCENTRATION CALIBRATION - 214 NM (LABORATORY VALIDATION CURVE)



mg/mL	Area (uV*s)	Recovery
0.5	3,571,531	99.73%
0.25	1,819,374	101.34%
0.1	714,287	98.63%
0.05	362,273	98.70%

Area = 7,142,626 C +9,775
Unweighted OLS through 4 levels | R2 0.99988
Sample area 4,690,907 = 0.6554 mg/mL (label: 0.5) * outside curve
x 2 mL x 10 = 13.11 mg

† 2 mL diluent, diluted x10 to the working 0.5 mg/mL

Validated 2026-08-31 | injector RSD 0.41% (n=6)

MAIN PEAK COMPARED WITH THE LABORATORY'S REFERENCE STANDARD





Native plotted readings with the laboratory's integration baselines and peak marks; nothing is smoothed or resampled.
Reference standard injected 2026-08-28 during the laboratory's validation of this curve; same instrument and method (retention -2.04%).

Understanding Your Report

What the measurements mean and how to read the supporting detail

Cagrilintide

Sample vial 3, injection 1 | Client report DAYL-CAGR-10-102626

Definitions, calculation detail, and scope

Lot # TNPS-CAG10-001 | Client: TrueNorth Peptide Supply

HOW TO READ THIS REPORT

Start with the result on page 1. Pages 2 and 3 show the curve, comparison, and peaks behind it.

01 **Recovered chromatogram**
The laboratory's trace, read back point for point from its report.

02 **Integrated peak table**
Every peak the laboratory integrated, and which one is the analyte.

03 **Validation curve**
Converts the peak area to a concentration for this analyte.

WHAT THE RECOVERED CHROMATOGRAM ADDS

How the chromatogram on this report was obtained

How it was recovered

The laboratory's data system draws the chromatogram in its report as vector data. Every vertex it drew was read back - 301 readings - and both axes were calibrated from the report's own tick marks. Integrating the recovered trace over the laboratory's baselines and peak marks reproduces the area in its peak table to within 0.25%.

What it can and cannot show

It shows every peak, shoulder and baseline the laboratory integrated, at the resolution the laboratory printed. It carries a single wavelength and no UV spectrum, so it cannot reveal a co-eluting compound the way diode-array data can.

Scope: the recovered chromatogram reproduces the laboratory's report. It does not re-measure the sample.

HOW THE PURITY RESULT WAS MEASURED

214 nm area percent, from the laboratory's own integration

The laboratory integrated each peak to its own baseline and named the analyte's peak in its processing method. Purity is that peak's share of the total integrated area; the shares below are recomputed from the areas, and each peak's area is checked against the recovered chromatogram.

Purity (%) = assigned peak area / total integrated peak area x 100

Peak	RT (min)	Area (uV*s)	Area %	Tailing	Plates	Role	Recovered
1	**22.140**	**4,690,907**	**99.86**	**1.16**	**167,993**	**Peak#1 - main**	**4,679,303 (-0.25%)**
2	22.677	6,604	0.14	1.05	207,736	impurity	-

Integrated peaks 2 | smallest 0.14% of total | injections 1

Area percent assumes every peak absorbs at 214 nm like the main peak; the analyte's peak is the one the laboratory's method names. Recovered areas are compared for the analyte's peaks of 1% or more.

WHAT THIS REPORT CAN AND CANNOT TELL YOU

The report explains the measurement; it does not decide how a material should be used

Observed evidence

The laboratory's chromatogram, its integration, and its validation curve.

Calculated results

Area-percent purity, concentration, projected amount, and calibration trace.

Method context

Retention time against the reference standard or the report's other vials, where on the same method.

Safety and regulatory status

No conclusion on safety, efficacy, fitness for use, or regulatory status.

This analytical record does not authorize or endorse manufacture, sale, marketing, distribution, or use of the material.